Cor Vasa 2013, 55(4):e364-e369 | DOI: 10.1016/j.crvasa.2013.03.004

Relationship of cardiorenal biomarkers for prediction of renal dysfunction in patients after heart transplantation

Lenka Hoškováa,*, Janka Franekováb, Ivan Máleka, Peter Sečník Jr.b, Jan Pirkc, Josef Kautznera, Ondřej Szárszoic, Antonín Jaborb
a Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika
b Pracoviště laboratorních metod, Institut klinické a experimentální medicíny, Praha, Česká republika
c Klinika kardiovaskulární chirurgie, Institut klinické a experimentální medicíny, Praha, Česká republika

Introduction: Renal dysfunction is a frequent complication after heart transplantation (HTx). It is mainly a result of ischaemic-reperfusion injury and/or the use of calcineurin inhibitors (CNIs). Serum creatinine and glomerular filtration rate (GFR) are widely used parameters for evaluation of renal function. However, serum creatinine is not accurate indicator, especially when kidney function changes. In our study, we focused on the assessment of microalbuminuria, cystatin C, lipocalin-2 (NGAL) and alpha-1-microglobulin (α-1M).

Aim: To describe the association between the measured biomarkers and renal functions during 6 months of follow-up.

Methods: We studied 77 patients undergoing HTx (mean age 50.1 ± 12.8, 64 males/13 females), using serial blood and urine sampling up to 6 months after the transplant. Serum cystatin C and NGAL were estimated by automated immunoanalysis (Abbott, Architect), α-1M was evaluated using nephelometry (Beckman, Immage). Estimation of glomerular filtration rate (eGFR) was based on serum concentrations of cystatin C. ACR ratio (g/mol) was calculated as the ratio of urinary albumin and creatinine.

Results: Renal dysfunction evaluated using the serum concentrations of cystatin was associated with increased concentrations of α-1M and NGAL. Elevated urinary concentration of α-1M on day 30 and during month 6 correlated with increased serum concentration of cystatin C during month 6 after HTx (p < 0.05 and p < 0.001, respectively). Elevated urinary concentration of NGAL on day 3 after HTx was associated with increase in the serum concentration of cystatin during month 6 after HTx (p < 0.01), however, no correlation was found with cystatin C early after surgery.
Patients with impaired renal function (necessity to use an elimination method) showed significantly higher serum NGAL on day 3 after HTx than in patient without renal impairment (p < 0.01). The value of albumin/creatinine ratio (ACR) gradually normalized during the follow-up, increased ACR being seen in only 16% of patients during month 3 after HTx. On the contrary, the urinary concentration of α-1M remains elevated during month 3 in 56% of patients. As for the association between ACR and α-1M, correlation coefficients were 0.372 for all paired values (n = 510, p < 0.0001). Serum cystatin C concentration values above 1.5 mg/L on day 10 after HTx were associated with worse prognosis (increased risk of death, p < 0.05).

Conclusion: The study has shown that evaluation of α-1M and NGAL on day 3 after the transplantation can predict the renal function 6 months after HTx. Increased serum cystatin C concentration on day 10 after HTx is associated with worse prognosis.

Keywords: Alpha-1-microglobulin; Cystatin C; Heart transplantation; Microalbuminuria; NGAL; Renal dysfunction

Received: January 9, 2013; Revised: March 3, 2013; Accepted: March 6, 2013; Published: August 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hošková L, Franeková J, Málek I, Sečník P, Pirk J, Kautzner J, et al.. Relationship of cardiorenal biomarkers for prediction of renal dysfunction in patients after heart transplantation. Cor Vasa. 2013;55(4):e364-369. doi: 10.1016/j.crvasa.2013.03.004.
Download citation

References

  1. B.O. Eriksen, K.R. Hoff, S. Solberg, et al., Prediction of acute renal failure after cardiac surgery: retrospective cross-validation of a clinical algorithm, Nephrology Dialysis Transplantation 18 (2003) 77-81. Go to original source... Go to PubMed...
  2. A. Greenberg, M.E. Thompson, B.J. Griffith, et al., Cyclosporine nephrotoxicity in cardiac allograft patients: a seven-year follow-up, Transplantation 50 (1990) 589-593. Go to original source... Go to PubMed...
  3. G. Parry, B. Meiser, G. Rabago, The clinical impact of cyclosporine nephrotoxicity in heart transplantation, Transplantation 69 (2000) S23-S26. Go to original source...
  4. R.C. Akker, E.M. Scholten, J.W. de Fijter, et al., Chronic cyclosporine nephrotoxicity in renal transplantation, Transplantation Reviews 18 (2004) 54-64. Go to original source...
  5. M.J. Mihatsch, G. Thiel, B. Ryffel, et al., Histopathology of cyclosporine nephrotoxicity, Transplantation Proceeding 20 (Suppl. 3) (1998) S759.
  6. A.O. Ojo, P.J. Held, F.K. Port, et al., Chronic renal failure after transplantation of a nonrenal organ, The New England Journal of Medicine 349 (2003) 931-940. Go to original source... Go to PubMed...
  7. L. Hošková, O. Viklický, I. Málek, et al., Ischaemic heart disease is a risk factor for renal failure after heart transplantation, International Journal of Cardiology 123 (3) (2008) 358-360. Go to original source... Go to PubMed...
  8. M. Tinami, L. Miller, B. Bastani, et al., Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center, Clinical Transplantation 11 (1997) 1-8.
  9. P. Ruggenenti, N. Perico, C.S. Amuchastegui, et al., Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine, American Journal of Kidney Diseases 24 (1994) 549-553. Go to original source... Go to PubMed...
  10. M. Waser, M. Maggiorini, U. Binswanger, et al., Irreversibility of cyclosporine-induced renal function impairment in heart transplant recipients, Journal of Heart and Lung Transplantation 12 (1993) 846-850. Go to PubMed...
  11. D.J.Goldstein, N. Zuech, V. Seghal, et al., Cyclosporine-associated end-stage nephropathy after cardiac transplantation, Transplantation 63 (1997) 644-666. Go to original source... Go to PubMed...
  12. L. Frimat, J.P. Villemot, L. Cormier, et al., Treatment of end-stage renal failure after heart transplantation, Nephrology Dialysis Transplantation 13 (1998) 2905-2908. Go to original source... Go to PubMed...
  13. M. Senechal, R. Dorent, S.T. Montcel, et al., End-stage of renal failure and cardiac mortality after heart transplantation, Clinical Transplantation 18 (2004) 1-6. Go to original source... Go to PubMed...
  14. A. Jabor, Poruchy funkce ledvin a nové biomarkery, Anesteziologie a intenzivní medicína 22 (1) (2011) 3-4.
  15. A. Jabor, J. Franeková, Proteinové markery tubulárních lézí u akutního poškození ledvin, FONS 20 (2010) 23-28.
  16. J. Franeková, A. Jabor, NGAL - klinické využití a nové poznatky, FONS 21 (2011) 40-41.
  17. A. Jabor, L. Straka, J. Franeková, Několik poznámek k současnému pohledu na určování eGFR, FONS 3 (2009) 27-28.
  18. V.R. Dhamidharka, Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis, American Journal of Kidney Diseases 40 (2002) 221-226. Go to original source... Go to PubMed...
  19. T. Keller, C.M. Messow, E. Lubos, et al., Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study, European Heart Journal 30 (2009) 314-320. Go to original source... Go to PubMed...
  20. J. Lassus, V.P. Harjola, R. Sund, et al., Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP, European Heart Journal 28 (2007) 1841-1847. Go to original source... Go to PubMed...
  21. B.P. Abraham, E.A. Frazier, R.W. Morrow, et al., Cystatin C and neutrophil gelatinase-associated lipocalin as markers of renal function in pediatric heart transplant recipients, Pediatric Transplantation 15 (6) (2011) 564-569. Go to original source... Go to PubMed...
  22. D. Kniepeiss, D. Wagner, G. Wirnsberger, et al., Serum cystatin is an easy to obtain biomarker for the onset of renal impairment in heart transplant recipients, Journal of Thoracic and Cardiovascular Surgery 140 (3) (2010) 688-693. Go to original source... Go to PubMed...
  23. O. Liangos, H. Tighiouart, M.C. Perianayagam, et al., Comparative analysis od urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass, Biomarkers 14 (6) (2009) 423-431. Go to original source... Go to PubMed...
  24. D. Heise, K. Rentsch, A. Braeuer, et al., Comparison of urinary neutrophil glucosaminidase-associated lipocalin, cystatin C, and α1-microglobulin for early detection of acute renal injury after cardiac surgery, European Journal of Cardio-Thoracic Surgery 39 (1) (2011) 38-43. Go to original source... Go to PubMed...
  25. A.S. Maisel, C. Mueller, R. Fitzgerald, et al., Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure (GALLANT) trial, European Journal of Heart Failure 13 (2011) 846-851. Go to original source... Go to PubMed...
  26. K. Damman, D.J. Van Veldhuisen, G. Navis, et al., Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate, Heart 96 (16) (2010) 1297-1302. Go to original source... Go to PubMed...
  27. M. Gerlichová, V. Černý, P. Dostál, P. Živný, Hodnocení spolehlivosti Neutrophil Gelatinase-Associated Lipocalin jako markeru renální dysfunkce v kardiochirurgii dospělých - prospektivní studie, Anesteziologie a intenzivní medicína 19 (6) (2008) 297-303.
  28. P. Przybylowski, J. Malyszko, J.S. Malyszko, Serum neutrophil gelatinase-associated lipocalin correlates with kidney function in heart alloograft recipients, Transplantation Proceedings 42 (2010) 1797-1802. Go to original source... Go to PubMed...
  29. S.S. Soni, C. Ronco, N. Katz, et al., Early diagnosis of acute kidney injury: the promise of novel biomarkers, Blood Purification 28 (3) (2009) 165-174. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.